Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer...
Gespeichert in:
| Veröffentlicht in: | Cochrane database of systematic reviews 2017-04, Vol.2017 (4) |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | |
| container_title | Cochrane database of systematic reviews |
| container_volume | 2017 |
| creator | Moraes, Fabio Y Perry, Luke A Penny-Dimri, Jahan C Ramson, Dhruvesh de Castria, Tiago B Bowman, Rayleen V Santos, Fábio N Fong, Kwun M Riera, Rachel |
| description | This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer (NSCLC). |
| doi_str_mv | 10.1002/14651858.CD012644 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6478330</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6478330</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2104-707e109ae9f018d626a70435b732a4bebf9f550548d938a8aa35ce3de31a4d5a3</originalsourceid><addsrcrecordid>eNpVkctKxDAUhosoOI4-gLssddExadLbRpAZbzCgC12X0_R0Gm2TkqQD8yS-ri3jiG7O_f848AfBJaMLRml0w0QSsyzOFssVZVEixFEwm2bhNDz-U58GZ859UMqTPEpnwddz1w0aiWxQfvZGaU-UblSpvLGOXIH2iryuQkaMJYdmza7JFq0b3CTrjG_QQr8j9XjjUBpdhdO5b5StwlaNdG8RfIcj3NSkQw_Og1eSaKND10HbEoljaAe9IRK0RHsenNTQOrz4yfPg_eH-bfkUrl8en5d361BGjIowpSkymgPmNWVZlUQJpFTwuEx5BKLEss7rOKaxyKqcZ5AB8Fgir5AzEFUMfB7c7rn9UHZYyfFHC23RW9WB3RUGVPF_o1VTbMy2SESacU5HANsDpDXOWax_tYwWkzXFwZriYA3_BgV_hHY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Cochrane Library</source><source>Alma/SFX Local Collection</source><creator>Moraes, Fabio Y ; Perry, Luke A ; Penny-Dimri, Jahan C ; Ramson, Dhruvesh ; de Castria, Tiago B ; Bowman, Rayleen V ; Santos, Fábio N ; Fong, Kwun M ; Riera, Rachel</creator><creatorcontrib>Moraes, Fabio Y ; Perry, Luke A ; Penny-Dimri, Jahan C ; Ramson, Dhruvesh ; de Castria, Tiago B ; Bowman, Rayleen V ; Santos, Fábio N ; Fong, Kwun M ; Riera, Rachel</creatorcontrib><description>This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer (NSCLC).</description><identifier>ISSN: 1465-1858</identifier><identifier>EISSN: 1465-1858</identifier><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD012644</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Medicine General & Introductory Medical Sciences</subject><ispartof>Cochrane database of systematic reviews, 2017-04, Vol.2017 (4)</ispartof><rights>Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 2017 The Cochrane Collaboration</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2104-707e109ae9f018d626a70435b732a4bebf9f550548d938a8aa35ce3de31a4d5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids></links><search><creatorcontrib>Moraes, Fabio Y</creatorcontrib><creatorcontrib>Perry, Luke A</creatorcontrib><creatorcontrib>Penny-Dimri, Jahan C</creatorcontrib><creatorcontrib>Ramson, Dhruvesh</creatorcontrib><creatorcontrib>de Castria, Tiago B</creatorcontrib><creatorcontrib>Bowman, Rayleen V</creatorcontrib><creatorcontrib>Santos, Fábio N</creatorcontrib><creatorcontrib>Fong, Kwun M</creatorcontrib><creatorcontrib>Riera, Rachel</creatorcontrib><title>Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer</title><title>Cochrane database of systematic reviews</title><description>This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer (NSCLC).</description><subject>Medicine General & Introductory Medical Sciences</subject><issn>1465-1858</issn><issn>1465-1858</issn><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVkctKxDAUhosoOI4-gLssddExadLbRpAZbzCgC12X0_R0Gm2TkqQD8yS-ri3jiG7O_f848AfBJaMLRml0w0QSsyzOFssVZVEixFEwm2bhNDz-U58GZ859UMqTPEpnwddz1w0aiWxQfvZGaU-UblSpvLGOXIH2iryuQkaMJYdmza7JFq0b3CTrjG_QQr8j9XjjUBpdhdO5b5StwlaNdG8RfIcj3NSkQw_Og1eSaKND10HbEoljaAe9IRK0RHsenNTQOrz4yfPg_eH-bfkUrl8en5d361BGjIowpSkymgPmNWVZlUQJpFTwuEx5BKLEss7rOKaxyKqcZ5AB8Fgir5AzEFUMfB7c7rn9UHZYyfFHC23RW9WB3RUGVPF_o1VTbMy2SESacU5HANsDpDXOWax_tYwWkzXFwZriYA3_BgV_hHY</recordid><startdate>20170426</startdate><enddate>20170426</enddate><creator>Moraes, Fabio Y</creator><creator>Perry, Luke A</creator><creator>Penny-Dimri, Jahan C</creator><creator>Ramson, Dhruvesh</creator><creator>de Castria, Tiago B</creator><creator>Bowman, Rayleen V</creator><creator>Santos, Fábio N</creator><creator>Fong, Kwun M</creator><creator>Riera, Rachel</creator><general>John Wiley & Sons, Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20170426</creationdate><title>Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer</title><author>Moraes, Fabio Y ; Perry, Luke A ; Penny-Dimri, Jahan C ; Ramson, Dhruvesh ; de Castria, Tiago B ; Bowman, Rayleen V ; Santos, Fábio N ; Fong, Kwun M ; Riera, Rachel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2104-707e109ae9f018d626a70435b732a4bebf9f550548d938a8aa35ce3de31a4d5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Medicine General & Introductory Medical Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moraes, Fabio Y</creatorcontrib><creatorcontrib>Perry, Luke A</creatorcontrib><creatorcontrib>Penny-Dimri, Jahan C</creatorcontrib><creatorcontrib>Ramson, Dhruvesh</creatorcontrib><creatorcontrib>de Castria, Tiago B</creatorcontrib><creatorcontrib>Bowman, Rayleen V</creatorcontrib><creatorcontrib>Santos, Fábio N</creatorcontrib><creatorcontrib>Fong, Kwun M</creatorcontrib><creatorcontrib>Riera, Rachel</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moraes, Fabio Y</au><au>Perry, Luke A</au><au>Penny-Dimri, Jahan C</au><au>Ramson, Dhruvesh</au><au>de Castria, Tiago B</au><au>Bowman, Rayleen V</au><au>Santos, Fábio N</au><au>Fong, Kwun M</au><au>Riera, Rachel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer</atitle><jtitle>Cochrane database of systematic reviews</jtitle><date>2017-04-26</date><risdate>2017</risdate><volume>2017</volume><issue>4</issue><issn>1465-1858</issn><eissn>1465-1858</eissn><eissn>1469-493X</eissn><abstract>This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) compared with standard chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer (NSCLC).</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><doi>10.1002/14651858.CD012644</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-1858 |
| ispartof | Cochrane database of systematic reviews, 2017-04, Vol.2017 (4) |
| issn | 1465-1858 1465-1858 1469-493X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6478330 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Cochrane Library; Alma/SFX Local Collection |
| subjects | Medicine General & Introductory Medical Sciences |
| title | Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T01%3A54%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20checkpoint%20inhibitors%20(anti%20PD-1%20or%20anti%20PD-L1)%20versus%20chemotherapy%20for%20second-%20or%20third-line%20treatment%20of%20metastatic%20non-small%20cell%20lung%20cancer&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Moraes,%20Fabio%20Y&rft.date=2017-04-26&rft.volume=2017&rft.issue=4&rft.issn=1465-1858&rft.eissn=1465-1858&rft_id=info:doi/10.1002/14651858.CD012644&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6478330%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |